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1. INTRODUCTION {#cam42234-sec-0005}
===============

Colorectal cancer (CRC) is one of the leading causes of cancer mortality worldwide.[1](#cam42234-bib-0001){ref-type="ref"} CRC is the third most common malignancy in European and American countries,[1](#cam42234-bib-0001){ref-type="ref"}, [2](#cam42234-bib-0002){ref-type="ref"} while in China, incidence and mortality rates have been increasing continuously in both colon and rectal cancer because of diet change and aging population.[3](#cam42234-bib-0003){ref-type="ref"} More than 90% of colorectal carcinomas are adenocarcinomas derived from epithelial cells of the colorectal mucosa.[4](#cam42234-bib-0004){ref-type="ref"} And the World Health Organization (WHO) pathologic classification of gastrointestinal lists a quantity of histologic subtypes of colorectal carcinomas, such as classic adenocarcinomas (AC), mucinous adenocarcinomas (MAC), signet ring cell carcinomas (SRCC) and other rare variants of colorectal carcinomas including squamous cell, neuroendocrine, adenosquamous, spindle cell, and undifferentiated carcinomas.[4](#cam42234-bib-0004){ref-type="ref"}, [5](#cam42234-bib-0005){ref-type="ref"} Apart from TNM staging system, histologic classification of CRC may influence the clinical features and outcome, thus, to clarify the effect of the varied histological subtypes will help clinicians choose the appropriate treatment strategy.

It is reported previously that approximately 10% of all CRC are MAC, and approximately 1% are SRCC.[6](#cam42234-bib-0006){ref-type="ref"}, [7](#cam42234-bib-0007){ref-type="ref"}, [8](#cam42234-bib-0008){ref-type="ref"} Because of the relatively rare incidence, the evaluation of clinicopathologic characteristics and survival of MAC and SRCC are difficult, recent studies suggest that MAC and SRCC were histological variants of CRC with different characteristics than AC, such as more advanced tumor stage at presentation, a younger patient age, more female patients and more distinct molecular features.[8](#cam42234-bib-0008){ref-type="ref"}, [9](#cam42234-bib-0009){ref-type="ref"} Additionally, it has been considered that SRCC and MAC carries a worse prognosis than AC.[10](#cam42234-bib-0010){ref-type="ref"} especially SRCC. However, the small sample size of these studies, which reduced the chance of detecting a true effect, may also cause unreliable conclusion.

The purpose of the study was to evaluate the effect of varied histological subtypes on clinical outcome and to determine the prognostic implications of MAC and SRCC compared with AC.

2. MATERIALS AND METHODS {#cam42234-sec-0006}
========================

2.1. Patient selection {#cam42234-sec-0007}
----------------------

This study was designed as a retrospective investigation of data collected for all patients who underwent definitive surgery without neoadjuvant chemoradiation or chemotherapy at Fudan University Shanghai Cancer Center (FDUCC) from 2007 to 2015. The inclusion criteria for this study were as follows: (a) history of primary colorectal cancer; (b) histologically confirmed adenocarcinoma (including AC, MAC and SRCC); (c) undergoing definitive surgery; (d) No evidence of distant metastasis at initial presentation; (e) no history of neoadjuvant therapy because neoadjuvant therapy caused tumor regression led to inaccurate staging. All data were collected from the database of FDSCC, including demographic features, preoperative tumor staging, details of the surgical procedure, postoperative histopathology, and follow‐up (date of last visit, date and site of tumor recurrence, date of death). Rectal cancer is defined as cancer located within 12 cm of the anal verge in our center and the colon cancer was divided into right‐side (including cecum, ascending colon, and right half of transverse colon) and left‐side (including left half of transverse colon, descending colon, and sigmoid colon) according to National Comprehensive Cancer Network guidelines. For each patient, the evaluation included a complete history and physical examination, including digital examination, complete blood count, hepatic and renal function tests, tumor marker measurement, colonoscopy and biopsy, computed tomography (CT) of the thorax and abdomen, magnetic resonance imaging (MRI) of the pelvis, and in selected patients, endorectal ultrasound and PET. Patient follow‐up was scheduled every three months during the first two years, and then every six months over the next three years. After five years, the frequency of follow‐up was extended to once each year. All patients were restaged according to the 7th edition of the TNM system from the American Joint Committee on Cancer (AJCC). The study was approved by the Institutional Review Board of the Fudan University Shanghai Cancer center and conducted in accordance with the Declaration of Helsinki of 1975 in its most recent version. Patients provided written informed consent prior to the study.

2.2. Pathological examination {#cam42234-sec-0008}
-----------------------------

The CRC of all patients was classified as AC, MAC, or SRCC according to the WHO pathologic classification of gastrointestinal tumors.[5](#cam42234-bib-0005){ref-type="ref"} MAC is defined by \>50% of the tumor volume composed of extracellular mucin, typically showing large glandular structures with pools of extracellular mucin. The presence of \>50% of tumor cells showing signet ring cell features characterized by a prominent intracytoplasmic mucin vacuole that pushes the nucleus to the periphery is classified as SRCC. AC is defined by classical glandular formation and configuration of the glandular structures.

2.3. Statistical analysis {#cam42234-sec-0009}
-------------------------

The overall survival (OS) and the disease‐free survival (DFS) rates were estimated by using the Kaplan‐Meier method, and comparison of three groups was applied by the log‐rank test. Cox proportional hazards regression was used for univariate and multivariate modeling and for examining the prognostic significance of the variables identified in the models. A *P*‐value of \<0.05 was considered statistically significant.

3. RESULTS {#cam42234-sec-0010}
==========

3.1. Demographic and clinicopathologic characteristics {#cam42234-sec-0011}
------------------------------------------------------

A total of 9015 patients with colorectal adenocarcinoma undergoing definitive surgery between 2007 and 2015 at FUSCC were enrolled in this study. However, 1010 of these patients were excluded because of neoadjuvant therapy. Therefore, 8005 cases remained for analysis, including 428 MAC and 75 SRCC. The demographic and clinicopathologic characteristics are listed in Table [1](#cam42234-tbl-0001){ref-type="table"}. Median follow‐up duration are 23.8, 26.9, and 26.9 months for AC, MAC, and SRCC groups, respectively.

###### 

Baseline clinicopathologic parameters

                                                    Tumor subtype   Total        *P* value            
  ------------------------- ----------------- ----- --------------- ------------ ----------- -------- ---------
  Patients (n)                                      7502 (93.7%)    428 (5.3%)   75 (0.9%)   8005      
  Sex (n)                   Male              Num   4429            235          54.0        4718.0    
                                              \%    59.0%           54.9%        72.0%       58.9%     
                            Female            Num   3073            193          21.0        3287      
                                              \%    41.0%           45.1%        28.0%       41.1%    0.017
  Age (year)                \<=35             Num   224             33           14          271       
                                              \%    3.0%            7.7%         18.7%       3.4%      
                            35‐55             Num   2312            158          33          2503      
                                              \%    30.8%           36.9%        44.0%       31.3%     
                            55‐75             Num   4365            206          26          4597      
                                              \%    58.2%           48.1%        34.7%       57.4%     
                            \>75              Num   601             31           2           634       
                                              \%    8.0%            7.2%         2.7%        7.9%     \<0.001
  Location                  Rectum            Num   4188            182          38          4408      
                                              \%    55.8%           42.5%        50.7%       55.1%     
                            Left hemicolon    Num   1606            80           8           1694      
                                              \%    21.4%           18.7%        10.7%       21.2%     
                            Right hemicolon   Num   1674            164          29          1867      
                                              \%    22.3%           38.3%        38.7%       23.3%     
                            Missing           Num   34              2            0           36        
                                              \%    0.5%            0.5%         0.0%        0.4%     \<0.001
  T Stage                   T1                Num   457             4            1           462       
                                              \%    6.1%            0.9%         1.3%        5.8%      
                            T2                Num   1370            39           1           1410      
                                              \%    18.3%           9.1%         1.3%        17.6%     
                            T3                Num   2714            174          36          2924      
                                              \%    36.2%           40.7%        48.0%       36.5%     
                            T4                Num   2926            208          37          3171      
                                              \%    39.0%           48.6%        49.3%       39.6%     
                            Missing           Num   35              3            0           38        
                                              \%    0.5%            0.7%         0.0%        0.5%     \<0.001
  N Stage                   N0                Num   3945            187          11          4143      
                                              \%    52.6%           43.7%        14.7%       51.8%     
                            N1                Num   2050            96           12          2158      
                                              \%    27.3%           22.4%        16.0%       27.0%     
                            N2                Num   1507            145          52          1704      
                                              \%    20.1%           33.9%        69.3%       21.3%    \<0.001
  lymphovascular invasion   ‐                 Num   5603            311          22          5936      
                                              \%    74.7%           72.7%        29.3%       74.2%     
                            \+                Num   1811            110          52          1973      
                                              \%    24.1%           25.7%        69.3%       24.6%     
                            Missing           Num   88              7            1           96        
                                              \%    1.2%            1.6%         1.3%        1.2%     \<0.001
  Nerve invasion            ‐                 Num   5915            340          20          6275      
                                              \%    78.8%           79.4%        26.7%       78.4%     
                            \+                Num   1533            85           55          1673      
                                              \%    20.4%           19.9%        73.3%       20.9%     
                            Missing           Num   54              3            0           57        
                                              \%    0.7%            0.7%         0.0%        0.7%     \<0.001
  CRM                       ‐                 Num   6888            365          63          7316      
                                              \%    91.8%           85.3%        84.0%       91.4%     
                            \+                Num   84              21           9           114       
                                              \%    1.1%            4.9%         12.0%       1.4%      
                            Missing           Num   530             42           3           575       
                                              \%    7.1%            9.8%         4.0%        7.2%     \<0.001

Abbreviation: CRM: Circumferential resection margin
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Patients with SRCC were younger than those with MAC or AC. There were significant differences in age, such that 18.7% of the patients with SRCC were \<35 years old compared with 7.7% and 3.0% of those with MAC and AC, respectively (*P* \< 0.001). Additionally, there was a much higher proportion of male in patients with SRCC (72.0%, *P* = 0.034) than the proportions for AC (59.0%) and MAC (54.9%). Compared with AC (22.3%), MAC (38.3%) and SRCC (38.7%, *P* \< 0.001) were located more frequently in the right hemicolon. Furthermore, SRCC and MAC were diagnosed at more advanced stages than AC (*P* \< 0.001 in both T and N stage); in particular, 63.9% of patients with SRCC were with N2 stage compared with AC (20.1%) and MAC (33.9%). The positive CRM status was observed in 1.6% (66/4109) and 1.4% (48/3321) in rectum and colon. Circumferential resection margin (CRM) positive was showed significantly more frequently for patients with SRCC than for those with AC and MAC (12% vs 4.9% vs 1.1%, *P* \< 0.001). Similarly, both lymphovascular invasion (69.3% vs 24.1% vs 25.7%, *P* \< 0.001) and nerve invasion (73.3% vs 19.9% vs 20.4%, *P* \< 0.001) occurred more frequently in patients with SRCC than those with AC and MAC.

3.2. Survival outcomes {#cam42234-sec-0012}
----------------------

The 5‐year DFS and 5‐year OS were significantly lower for the SRCC than AC and MAC (*P* \< 0.001). The 5‐year OS for the patients with SRCC was 64.2% whereas those with AC and MAC were 82.0% and 64.2% (*P* \< 0.001). Similarly, the 5‐year DFS was 71.6% for patients with AC, 64.3% for patients with MAC, and 54.4% for patients with SRCC (*P* \< 0.001). The Kaplan‐Meier survival curves for different histological subtypes are displayed in Figure [1](#cam42234-fig-0001){ref-type="fig"}.

![Kaplan‐Meier Curve Plotting the 5‐year OS (A) and DFS (B) Corresponding to the Three Different Histologic Subtypes](CAM4-8-3411-g001){#cam42234-fig-0001}

In addition to the histological subtypes of cancer (AC, MAC, or SRCC), factors associated with survival on univariate analysis were age, T stage, N stage, lymphovascular invasion, nerve invasion, CRM, and tumor location. Most of these factors remained independent prognostic factors except tumor location in the multivariate Cox model (Table [2](#cam42234-tbl-0002){ref-type="table"}). However, there were no significant differences in OS and DFS between SRCC, MAC and AC after multivariate Cox regression analysis, no matter AC was compared with SRCC or MAC.

###### 

Independent prognostic factors in multivariable analysis of overall survival and disease‐free survival

                              OS        DFS                                     
  --------------------------- --------- ------- ------------- --------- ------- -------------
  Age                         \<0.001                         \<0.001            
  35‐55 vs \<35               0.043     1.321   0.801‐2.180   0.107     1.153   0.803‐1.656
  55‐75 vs \<35               0.001     1.724   1.053‐2.821   0.003     1.423   0.997‐2.031
  \>=75 vs \<35               \<0.001   3.990   2.357‐6.756   \<0.001   1.886   1.262‐2.817
  T stage                     \<0.001                         \<0.001            
  T2 vs T1                    0.161     1.810   0.769‐4.259   0.161     1.487   0.842‐2.627
  T3 vs T1                    0.037     2.382   1.045‐5.432   0.004     2.208   1.282‐3.805
  T4 vs T1                    0.001     4.109   1.816‐9.295   \<0.001   3.141   1.831‐5.388
  Vascular thrombosis                                                            
  (+) vs (‐)                  \<0.001   1.592   1.328‐1.910   \<0.001   1.419   1.225‐1.643
  Nerve invasion                                                                 
  (+) vs (‐)                  0.013     1.264   1.057‐1.513   \<0.001   1.599   1.386‐1.843
  CRM                                                                            
  (+) vs (‐)                  \<0.001   2.495   1.781‐3.495   0.014     1.515   1.095‐2.097
  N stage                     \<0.001                         \<0.001            
  N1 vs N0                    \<0.001   1.608   1.271‐2.036   \<0.001   1.464   1.271‐2.036
  N2 vs N0                    \<0.001   3.408   2.697‐4.308   \<0.001   2.925   2.436‐3.513
  Tumor subtype               0.690                           0.307              
  MAC vs AC                   0.459     1.112   0.822‐1.505   0.915     1.018   0.790‐1.311
  SRCC vs AC                  0.628     1.173   0.669‐2.059   0.128     0.678   0.403‐1.140
  Location                    0.003                           0.119              
  Left hemicolon vs rectum    0.596     0.946   0.765‐1.169   0.437     0.942   0.798‐1.111
  Right hemicolon vs rectum   0.003     1.308   1.082‐1.580   0.118     1.130   0.967‐1.320

John Wiley & Sons, Ltd

3.3. N stage‐stratified survival outcomes of SRCC {#cam42234-sec-0013}
-------------------------------------------------

We performed an N stage‐stratified survival analysis to evaluate the survival outcomes more precisely. Our data suggested that when analyzed based on node positive group, there were no significant differences of 3y‐DFS and 5y‐DFS between AC, MAC, and SRCC, although patients with SRCC and MAC performed a trend toward shorter survival than patients with AC (3y‐DFS: 54.9% vs 57.10% vs 66.2%, *P* = 0.136, Table [3](#cam42234-tbl-0003){ref-type="table"}). Furthermore, AC, MAC and SRCC had almost the same 3y‐DFS stratified by N2 stage (53.3% vs 51.7% vs 51.9%, *P* = 0.996), and the same result showed in 5y‐DFS (43.8% vs 43.8% vs 51.9%, *P* = 0.996). (Table [3](#cam42234-tbl-0003){ref-type="table"} and Figure [2](#cam42234-fig-0002){ref-type="fig"}).

###### 

DFS for patients in All/N+/N2 group, corresponding to adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma

         All Group   N+       N2                                                    
  ------ ----------- -------- --------- -------- -------- ------- -------- -------- -------
  AC     77.80%      71.60%             66.20%   57.80%           53.30%   43.80%    
  MAC    67.70%      64.30%             57.10%   51.80%           51.70%   43.80%    
  SRCC   60.50%      54.40%   \<0.001   54.90%   54.90%   0.136   51.90%   51.90%   0.996
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![DFS for Patients in All (A)/N+ (B)/N2 (C) Group, Corresponding to Adenocarcinoma, Mucinous Adenocarcinoma, and Signet Ring Cell Carcinoma. Levels of significance are listed in Table [3](#cam42234-tbl-0003){ref-type="table"}](CAM4-8-3411-g002){#cam42234-fig-0002}

4. DISCUSSION {#cam42234-sec-0014}
=============

To our knowledge, this study was reported as the largest Chinese cohort investigating patients with AC, MAC, and SRCC and analyzed the relationship between pathologic types and clinical features as well as survival outcomes in 8005 patients with colorectal cancer under a single‐center database. We found that SRCC and MAC were more common in male patients and more likely to lead to lymph node metastasis, lymphovascular invasion, and perineural invasion. We also found that both MAC and SRCC, which presented at a more advanced T stage compared with AC, occurred more often in young patients and right‐sided colon cancer. In addition, CRM positivity was higher in MAC and SRCC compared with AC. For survival outcomes, we found that the 5‐year OS of SRCC was significantly lower than that of MAC and AC, while the 5‐year OS of MAC was much lower than AC. However, neither MAC nor SRCC was an independent predictor of decreased survival on multivariate.

Among 8005 patients recruited in our study, rates of SRCC, MAC, and AC were 0.9%, 5.3%, and 93.7%, respectively, which were consistent with population‐based data sets reported in the Western countries and Asia.[10](#cam42234-bib-0010){ref-type="ref"} An analysis of 164,628 CRC patients enrolled from 1991 to 2000 based on SEER database in US found that the rates of SRCC, MAC, and AC were 0.9%, 10.3%, and 88.8%, respectively.[1](#cam42234-bib-0001){ref-type="ref"} Another analysis from the National Cancer Data Base, which included 244,794 CRC patients, reported that SRCC accounted for 0.9%, MAC accounted for 10.4%, and AC accounted for 88.6% of all CRC histologic types.[10](#cam42234-bib-0010){ref-type="ref"} We could draw a conclusion from the data above that the proportion of MAC is five to ten times more than SRCC but is still much less than AC. Another analysis based on 273 patients with rectal cancer in India reported that proportion of SRCC was 13.6%, whereas the proportion of MAC was only 7.7%.[11](#cam42234-bib-0011){ref-type="ref"} The inconsistency between publications implies the proportion of SRCC and MAC may associate with different races and tumor sites.

We found that the proportion of male patients in SRCC was 72.0%, which was significantly higher than the proportion of females. This conclusion was consistent with the study by Wei et al[12](#cam42234-bib-0012){ref-type="ref"} who analyzed 61 CRC patients with SRCC from China. Other analyses performed in the United States,[9](#cam42234-bib-0009){ref-type="ref"}, [10](#cam42234-bib-0010){ref-type="ref"} India,[11](#cam42234-bib-0011){ref-type="ref"} and Singapore[13](#cam42234-bib-0013){ref-type="ref"} reported similar proportions for gender SRCC and MAC. However, another report by Tan et al[14](#cam42234-bib-0014){ref-type="ref"} which analyzed 2454 cases of Chinese CRC patients, did not find any difference between proportion of male and female patients in SRCC or MAC histology.

In addition to the features mentioned above, we found that MAC and SRCC more frequently occurred in right‐sided colon compared with AC. This finding is consistent with previous reports.[10](#cam42234-bib-0010){ref-type="ref"}14 However, an analysis based on SEER dataset in the US reported that MAC was more common in the left side of the colon, and another report in 2016 focusing on Chinese patients reported that SRCC more often presented in the left side of the colon and in the rectum.[15](#cam42234-bib-0015){ref-type="ref"} Prevalence of differences between right‐sided and left‐sided colon cancer was a prominent topic at the 2016 ASCO meeting,[16](#cam42234-bib-0016){ref-type="ref"} and it was reported that the activation of MSI, which was a major reason of hereditary CRC such as Lynch syndrome,[17](#cam42234-bib-0017){ref-type="ref"} occurred more frequently in right‐sided colon. MAC had been reported to more frequently show MSI phenotype.[18](#cam42234-bib-0018){ref-type="ref"}, [19](#cam42234-bib-0019){ref-type="ref"}, [20](#cam42234-bib-0020){ref-type="ref"} Recently, Shen et al[12](#cam42234-bib-0012){ref-type="ref"} divided SRCC into two groups according to the percentage of signet ring cells in tumors \>50% and \<50% and analyzed 13 genes associated with hereditary tumor syndrome, including MLH1, MSH2, MSH6, and PMS2, and found no difference of pathological mutation between two groups. However, 79.6% of SRCC carried at least one pathogenic mutation. Therefore, it warrants further study whether different histology results in the different molecular features between right‐sided and left‐sided colon cancer.

In accordance with the majority of published studies before,[10](#cam42234-bib-0010){ref-type="ref"}, [11](#cam42234-bib-0011){ref-type="ref"}, [21](#cam42234-bib-0021){ref-type="ref"}, [22](#cam42234-bib-0022){ref-type="ref"}, [23](#cam42234-bib-0023){ref-type="ref"} SRCC was more common in young patients and associated with higher T stage, higher N stage, lymphovascular invasion and perineural invasion. This result suggested that SRCC had a stronger tendency of invasion and metastasis compared with AC, and patients with SRCC may already have subclinical metastases even before undergoing radical surgery. CRM positivity was much higher in SRCC than MAC or AC, in our study, as the rate of CRM positivity in SRCC, MAC, and AC was 12.0%, 4.9%, and 1.1%, respectively. Another analysis which focused on rectal cancer in India reported a positive CRM rate of 13.6% in SRCC, which was also significantly higher than AC.[11](#cam42234-bib-0011){ref-type="ref"} The reason of higher CRM positivity of SRCC may be explained by the fact that SRCC presented with later T stage more frequently. Since CRM positivity means that the patient does not receive R0 surgery and emerges as a significantly negative prognostic factor, patients with SRCC may require a more extensive resection compared with those with AC, and intraoperative frozen sections should be used if necessary. For MAC, its clinical features were between AC and SRCC.

Contrary to our expectations, we found that neither SRCC nor MAC was an independent prognostic factor for DFS and OS in patients with CRC after adjustment for other risk factors. The prognostic significance of SRCC and MAC in CRC patients has long been controversial. In some studies, SRCC and MAC were considered to be a negative prognostic factor for CRC.[23](#cam42234-bib-0023){ref-type="ref"}, [24](#cam42234-bib-0024){ref-type="ref"}, [25](#cam42234-bib-0025){ref-type="ref"} An analysis based on NCBD dataset reported that SRCC was an independent negative prognostic factor for colorectal cancer, while MAC was a negative prognostic factor only for rectal cancer, but not for colon cancer.[10](#cam42234-bib-0010){ref-type="ref"} Another study based on SEER dataset found that MAC was an independent negative prognostic factor for rectal cancer, a protective prognostic factor for right‐sided colon cancer and had no prognostic effect in left‐sided colon cancer.[9](#cam42234-bib-0009){ref-type="ref"} The results of these two studies based on large population suggested that SRCC and MAC in different primary site may have different prognostic effect on OS of CRC patients. However, an analysis based on a small sample of Indian population showed no significant difference of OS among MAC, SRCC, and AC in rectal cancer.[11](#cam42234-bib-0011){ref-type="ref"} A study performed in Italy also suggested that there was no significant association of MAC with the prognosis of CRC patients compared with non‐MAC.[26](#cam42234-bib-0026){ref-type="ref"}

Our results suggest that histological subtypes, such as SRCC and MAC, may not be an independent prognostic factor of CRC patients, instead, SRCC and MAC present a more advanced stage to indirectly affect the prognosis of CRC patients, as previously reported.[9](#cam42234-bib-0009){ref-type="ref"}, [13](#cam42234-bib-0013){ref-type="ref"}, [26](#cam42234-bib-0026){ref-type="ref"} To confirm our hypothesis, we performed a subgroup analysis of N stage and found that although DFS of SRCC and MAC was significantly shorter than that of AC in the univariate analysis, there was no significant difference of DFS among SRCC, MAC and AC in patients with positive lymph node metastases, especially in patients with N2 stage. Our findings highlight the importance of early diagnosis and treatment of CRC. If a patient received the resection with an early stage, that was, with no lymph node metastasis, lymphovascular invasion or perineural invasion, the histology itself may not affect the survival outcome of the patient.

There are several limitations. First, the patient data we collected were from a single cancer center which may lead to selection bias. However, the level of pathological diagnosis in our center is of leading in China, and the highly standardized pathological diagnosis minimized the diagnostic bias. Then, the study was not a prospective cohort, which had some of the inherent inadequacies of retrospective investigations. For example, we only evaluated patients undergoing curative surgery, the other patients of colorectal cancer without radical surgery could not be evaluated because of information loss. And because many patients were from other cities and accepted adjuvant chemotherapy in local hospitals after surgery, it was difficult for us to ensure the strict implementation and accurate evaluation of chemotherapy in the follow‐up process. Furthermore, its statistical power was limited due to the rarity of SRCC. However, we believe that the 75 patients of SRCC assure the statistical power quite well.

5. CONCLUSION {#cam42234-sec-0015}
=============

MAC and SRCC are presented at a higher T stage, N stage as well as higher incidence of lymphovascular invasion and nerve invasion, which usually considered as independent prognostic factors to poor survival. However, our data indicated that when analyzed through multivariable analysis, the difference in survival between SRCC, MAC and AC was no longer significant, especially when stratified by N stage. Therefore, more research, including molecular mechanism and gene expression, is needed to clarify the relationship between SRCC and N stage, which may benefit the precision medical treatment based on histologic type.
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